Table 3.
Aβ42/40 (Elecsys) | p-tau217 | NfL | GFAP | |||||
---|---|---|---|---|---|---|---|---|
| ||||||||
OR | AUC | OR | AUC | OR | AUC | OR | AUC | |
Conversion to AD-dementia within 4 years | ||||||||
Base model | 0.54 | 0.70 | 3.87 | 0.82 | 1.66 | 0.67 | 1.98 | 0.74 |
Model including creatine and BMI | 0.55 | 0.71 | 4.03 | 0.83 | 1.69 | 0.67 | 1.95 | 0.74 |
Conversion to all-cause dementia within 4 years | ||||||||
Base model | 0.65 | 0.65 | 2.48 | 0.73 | 2.21 | 0.71 | 1.79 | 0.70 |
Model including creatine and BMI | 0.65 | 0.67 | 2.46 | 0.74 | 2.31 | 0.71 | 1.78 | 0.71 |
Odds ratio of plasma biomarkers from logistic regression to discriminate participants who remained stable vs. those who converted to AD dementia or all-cause dementia. Odds ratio represents the increased odds of converting to dementia for each increase in standard deviation biomarker value. Models included age and sex as covariates. Bolded values indicate when significant improvement in plasma estimate was seen in models including creatinine and BMI based on bootstrapping. Significance of all plasma odds ratio is p < 0.001.
Abbreviations: Aβ, beta-amyloid; AUC, area under the curve; BMI, body mass index; GFAP, glial fibrillary acidic protein; NfL, neurofilament light; p-tau217, phosphorylated tau 217; OR, odds ratio